Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
World Health Organization India Country Office, New Delhi, India.
J Gastroenterol Hepatol. 2019 Feb;34(2):321-329. doi: 10.1111/jgh.14466. Epub 2018 Sep 26.
Burden of hepatitis C in India is not known. We therefore conducted a systematic review of the available data on anti-hepatitis C virus (HCV) seroprevalence in the Indian population.
We searched several publication databases for English language papers that reported data on anti-HCV seroprevalence from India and also identified other unpublished sources of such data. Data on groups likely to represent seroprevalence in general population and in selected high-risk groups were extracted and subjected to meta-analysis.
Of the 3995 published papers and 94 additional data sources identified, 327 were selected; these provided 414 anti-HCV seroprevalence data points. Pooled anti-HCV seroprevalence rates in community-based studies, blood donors, and pregnant women were 0.85% (95% confidence interval: 0.00-3.98%), 0.44% (0.40-0.49), and 0.88% (0.21-1.90), respectively. Among groups considered at high risk of HCV, pooled anti-HCV seroprevalence rates were as follows: people living with HIV (40 studies from 17 states: 3.51% [2.43-4.76]), persons on maintenance hemodialysis (37, 13; 19.23% [13.52-25.65]), people who inject drugs (46, 14; 44.71% [37.50-52.03]), multi-transfused persons (38, 12; 24.06% [20.00-28.36]), persons with sexually transmitted diseases (7, 5; 4.10% [0.98-9.04]), and those with high-risk sex behavior (6, 5; 4.06% [1.79-7.10]).
Community-based data on HCV seroprevalence in India were limited. Large amount of data on blood donors and pregnant women were identified, with pooled anti-HCV seroprevalence rates of 0.44% and 0.88%, respectively. Among high-risk groups, anti-HCV prevalence was higher among people living with HIV, those with sexually transmitted diseases, high-risk sex behavior or injection drug use, and those receiving hemodialysis or frequent transfusions.
印度的丙型肝炎负担尚不清楚。因此，我们对印度人群中抗丙型肝炎病毒（HCV）血清流行率的现有数据进行了系统评价。
我们在多个出版物数据库中搜索了报道印度抗 HCV 血清流行率数据的英文论文，并确定了其他未发表的此类数据来源。提取了代表一般人群和选定高危人群血清流行率的数据，并进行了荟萃分析。
在 3995 篇已发表的论文和 94 个额外的数据来源中，有 327 篇被选中；这些提供了 414 个抗 HCV 血清流行率数据点。基于社区的研究、献血者和孕妇的抗 HCV 血清流行率分别为 0.85%（95%置信区间：0.00-3.98%）、0.44%（0.40-0.49）和 0.88%（0.21-1.90）。在被认为有 HCV 高风险的人群中，抗 HCV 血清流行率分别为：艾滋病毒感染者（来自 17 个州的 40 项研究：3.51%[2.43-4.76]）、维持性血液透析患者（37 项，13 项；19.23%[13.52-25.65]）、注射吸毒者（46 项，14 项；44.71%[37.50-52.03]）、多次输血者（38 项，12 项；24.06%[20.00-28.36]）、性传播疾病患者（7 项，5 项；4.10%[0.98-9.04]）和高危性行为者（6 项，5 项；4.06%[1.79-7.10]）。
印度基于社区的 HCV 血清流行率数据有限。我们确定了大量献血者和孕妇的数据，抗 HCV 血清流行率分别为 0.44%和 0.88%。在高危人群中，艾滋病毒感染者、性传播疾病患者、高危性行为或注射吸毒者、接受血液透析或频繁输血者的抗 HCV 患病率较高。
